Previous Close | 16.49 |
Open | 16.31 |
Bid | 14.60 x 1100 |
Ask | 16.50 x 800 |
Day's Range | 16.31 - 16.95 |
52 Week Range | 6.40 - 18.91 |
Volume | |
Avg. Volume | 12,785 |
Market Cap | 90.019M |
Beta (5Y Monthly) | 1.51 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.86 |
Earnings Date | N/A |
Forward Dividend & Yield | 2.34 (13.98%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for FBIOP
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event wi
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “We continue to work closely with our third-party contract manufacturing organization to expeditiously resolve the deficiencies noted in t
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial guidance of $12.0 million New Drug Application for rosacea treatment candidate DFD-29 accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDAL